News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Direct Flow Medical, Inc. Transcatheter Aortic Valve System Shown to Virtually Eliminate Aortic Regurgitation With No Vascular Complications in DISCOVER CE Mark Trial



10/23/2012 9:21:18 AM

SANTA ROSA, Calif.--(BUSINESS WIRE)--Direct Flow Medical, Inc., a transcatheter heart valve innovator focused on improving patient outcomes, announced that its DISCOVER CE Mark Trial met its primary mortality endpoint. The study also demonstrated that greater than 95 percent of patients had mild or less aortic regurgitation, and no patients experienced vascular complications. The DISCOVER Trial results were presented yesterday at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in Miami, Florida.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES